Tailored and Focused Immuno-Oncology and Biomarker Conference in 2026
2nd Immuno-Oncology and Biomarker Summit 2026
📍 Philadelphia, USA
📅 19–20 October 2026
Event Overview
The 2nd Edition Immuno-Oncology & Biomarker Conference, organized by Veridon Global, will take place on 19–20 October 2026, bringing together leaders from pharma, biotech, and clinical research. The conference will explore how biomarker-driven precision medicine is evolving through advances in AI, multi-omics, and emerging technologies such as liquid biopsy, MRD, radiomics, and spatial biology.
The program also highlights the growing role of advanced biomarker strategies in enabling targeted therapies, alongside key developments in immuno-oncology, including next-generation treatments, combination strategies, and smarter patient selection. With a focus on real-world application, discussions will address how these innovations are moving from research into clinical practice.
Designed to foster collaboration and fresh thinking, the event brings together science, strategy, and commercial perspectives to drive meaningful progress in precision oncology.
The Biomarker Blueprint for Immuno Oncology
Explore The Key Highlights
Next-Generation Immunotherapies
ADCs, bispecific antibodies, and cellular therapies
Biomarker-Driven Precision Oncology
From discovery to clinical impact
Strategic Combination Approaches
Enhancing efficacy and overcoming resistance
Translational Research & Immune Monitoring
Preclinical models and real-time technologies for better decision-making
Biomarker Integration in IO Trials
Advancing cancer vaccines and oncolytic viruses
Who Should Attend
Pharma, Biotech, Industry Professionals and Academia in
Immuno-Oncology
Biomarkers
Cell Therapies
Antibodies
Translational Research
Diagnostics
Precision Medicine
Clinical Trials
Drug Development
Commercialization
Cancer Vaccines
Oncolytic Viruses
Genomics
Bioinformatics
Investment
Final Decision Makers
Chief Executive Officer
Chief Scientific Officer
President
Vice President
Executive Director
Assoicate/Senior Director
Manager/Sr. Manager
Head of Department
Attendee Demographics
Why Attend
Exclusive Insights
Latest advances in immuno-oncology, biomarkers, and precision oncology.
Collaboration
Connect with pharma, biotech, and academic leaders.
Combination Strategies
Explore checkpoint inhibitors, ADCs, and cell therapies.
Biomarker Integration
Personalization, trial optimization, and patient selection.
Regulatory Trends
Updates on global frameworks for IO and biomarker-based therapies.
2026 USA Edition Speakers
From Immuno-Oncology Visionaries
to Biomarker Science Pioneers
Speakers To Be Announced
John Maher
John Maher
Sophia Karagiannis
Sophia Karagiannis
Seema Patel
Seema Patel
Mark Eccleston
Mark Eccleston
Colin Self
Colin Self
Simon Plyte
Simon Plyte
John Bridgeman
John Bridgeman
Manel Kraiem
Manel Kraiem
Chandan Seth Nanda
Chandan Seth Nanda
Kathrin Heinzmann
Kathrin Heinzmann
Prasun Chakraborty
Prasun Chakraborty
Rene Hoet
Rene Hoet
Amit Jathoul
Amit Jathoul
Amer Alghabban
Amer Alghabban
Maximilien Grandclaudon
Maximilien Grandclaudon
Pierre Eftekhari
Pierre Eftekhari
Libby Naylor
Libby Naylor
Agata Drewniak
Agata Drewniak
Martin Merello
Martin Merello
Mark Exley
Mark Exley
Frederick Campbell
Frederick Campbell
Matthew Jones
Matthew Jones
Karthikeyan Devaraju
Karthikeyan Devaraju
Alok Pandey
Alok Pandey
Raif Yuecel
Raif Yuecel
Agenda
| Time | Track 1: Immuno-Oncology | Track 2: Biomarkers & CDx |
|---|---|---|
| 8:00 — Registration and Refreshments | ||
| 8:50 | Welcome Note by Veridon Global | |
| 8:55 | Opening Address by the Chairperson | |
| 9:00 | CAR-T, TCR & Next-Gen Cell Therapies in Solid Tumors | Multi-Omics Integration: From Data to Decision-Making |
| 9:25 | Bispecifics & T-cell Engagers: Winning Design Strategies | Spatial Biology & Single-Cell: Clinical Readiness vs Research |
| 9:50 | ADC + IO Combinations: Redefining Targeted Immunotherapy | Liquid Biopsy: Beyond ctDNA — What's Next? |
| 10:15 — Morning Refreshments and Poster Presentations | ||
| 10:45 | Tumor Microenvironment: Converting Cold Tumors into Responders | Biomarkers in Early Drug Development |
| 11:10 | Mechanisms of Resistance: Primary vs Acquired | Emerging Biomarkers: HER2-low, KRAS & Beyond |
Download the full agenda to view all sessions, panel discussions, and networking slots.
Download Agenda Download Past Edition Agenda| Time | Track 1: Immuno-Oncology | Track 2: Biomarkers & CDx |
|---|---|---|
| 8:00 — Registration and Refreshments | ||
| 8:50 | Welcome Note by Veridon Global | |
| 8:55 | Opening Address by the Chairperson | |
| 9:00 | Allogeneic & Off-the-Shelf Cell Therapies | Drug–Diagnostic Co-Development: Aligning Clinical & Regulatory Strategy |
| 9:25 | Novel Checkpoint Targets (LAG-3, TIGIT, etc.) | CDx Assay Development and Analytical Validation Strategies |
| 9:50 | Immune Engagers Beyond CD3 | CDx in Clinical Trials: Biomarker Integration & Endpoint Design |
| 10:15 — Morning Refreshments and Poster Presentations | ||
| 10:45 | Immunotherapy in Early Lines & Adjuvant Settings | Multiplex & Pan-Cancer CDx: Moving Beyond Single Biomarkers |
| 11:10 | IO in Rare & Hard-to-Treat Tumors | CDx as a Bottleneck in Clinical Trials |
Download the full agenda to view all sessions, panel discussions, and networking slots.
Download Agenda Download Past Edition Agenda9:25 Bispecifics & T-cell Engagers: Winning Design Strategies
9:50 ADC + IO Combinations: Redefining Targeted Immunotherapy
Our Esteemed Sponsors & Exhibitors
Silver Sponsors
Bronze Sponsors
Exhibitors
Networking Sponsors
Media Partners
LISTING PARTNERS
Past Sponsors
Why Sponsor?
Dedicated Prime Speaking Slot
Exhibition Opportunity
One-to-One Meetings
Pre-Qualified Leads
High-Level Networking
Brand Impact
View The Glimpses Of Our Past Edition
View The Glimpses Of Our Past Edition
Evidence 360 USA Edition
Elevate your brand where crypto’s most influential minds connect beyond the conference floor.
Venue
Philadelphia, USA
Contact Our Team Today
Biomarker innovation begins.
Partnerships
